Phase 2 Lymphoma Trial, Recruiting NCT05933967 Sponsor: Shandong Cancer Hospital and Institute Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT05933967
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with a specific type of lymphoma called Double Expression Diffuse Large B-cell Lymphoma
  • People aged between 18 and 70 years old
  • People whose general health and ability to perform daily activities falls within an acceptable range (a score of 0–2 on a standard medical scale — confirm with trial site)
  • People whose lymphoma has been classified at a certain stage of spread (Stage II, III, or IV — confirm with trial site)
  • People whose blood and body test results meet the laboratory standards required by the trial
  • People who are expected to live for at least 3 months

Who may not be able to join:

  • People whose lymphoma has spread to the brain or spinal cord (central nervous system)
  • People with uncontrolled heart, blood vessel, or brain circulation problems, blood clotting disorders, or connective tissue diseases
  • People with uncontrolled infections, including hepatitis B, hepatitis C, or HIV/AIDS
  • People who are being considered for or are planning to have a stem cell or organ transplant
  • People who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: zengjun Li, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences

Phone: 13642138692

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shandong Cancer Hospital and Institute
Registry
ClinicalTrials.gov
Start date
1 June 2023
Est. completion
30 December 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

complete response rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov